Xylem Inc. (XYL) vs. IDEX CORP /DE/ (IEX) Stock Comparison & Valuation | Edwyn

Edwyn

Edwyn Search companies, tickers, CIKs…⌘K

Xylem Inc. (XYL) vs. IDEX CORP /DE/ (IEX) Stock Comparison & Valuation | Edwyn

Updated 2026-02-01 14:38 UTC

This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.

Xylem shows stronger top-line growth and a healthier balance sheet than IDEX but weaker margins and a higher P/E, producing a mixed signal that leaves valuation close to neutral.

Actionable Takeaway

If you believe Xylem can convert its above-IEX revenue growth (16.3%) into substantial margin and ROIC expansion toward IDEX levels (Operating Margin 20.7%, ROIC 12.9%), then consider buying/adding because the market is paying a premium P/E (37.8x) that could compress if margins improve; otherwise, if you expect margins to remain nearer current levels (Operating Margin 11.8%) and the market to re-rate toward IEX multiples, then reduce exposure or avoid new purchases because the P/E-implied fair price is $107.34 (current downside -22.1%).

Xylem's current price ($137.88) is below IEX-implied downside-adjusted fair value ($107.34) on a P/E basis but sits inside IEX-implied range ($107.34 - $159.48) and inside its historical band ($124.09 - $151.67). The -22.1% implied downside vs the $107.34 P/E-implied price highlights risk if market re-rates to IEX multiples. Mixed signals from P/S and EV multiples contribute to the ambiguity.

Supporting Metrics

Key Risks

Persistent margin gap: Operating Margin 11.8% (XYL) vs 20.7% (IEX) prevents re-rating
Valuation compression risk: high P/E at 37.8x relative to IDEX 29.4x could reverse if growth disappoints
Reliance on growth converting to profitability: Revenue Growth 16.3% must translate into higher margins/ROIC or valuation is at risk